The Efficacy and Safety of Sphenopalatine Ganglion Pulsed Radiofrequency Treatment for Cluster Headache

Sponsor
Beijing Tiantan Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT03567590
Collaborator
Beijing Sanbo Brain Hospital (Other), Jilin Province People's Hospital (Other)
80
3
2
30.1
26.7
0.9

Study Details

Study Description

Brief Summary

The investigators aim to investigate the effectiveness and safety of sphenopalatine ganglion pulsed radiofrequency on cluster headache.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Pulsed Radiofrequency treatment
  • Procedure: Nerve Block treatment
N/A

Detailed Description

The investigators aim to investigate whether the sphenopalatine ganglion pulsed radiofrequency treatment is better than traditional sphenopalatine ganglion nerve block technology and provides medical evidence for the clinical application and promotion of sphenopalatine ganglion pulsed radiofrequency treatment to provide a minimally invasive, safe, and effective treatment for patients with cluster headache who do not respond to drug treatment.

Study Design

Study Type:
Interventional
Actual Enrollment :
80 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
A Prospective, Multicentre, Randomized, Controlled, Blinded-endpoint Study to Evaluate the Efficacy and Safety of Sphenopalatine Ganglion Pulsed Radiofrequency Treatment for Cluster Headache
Actual Study Start Date :
Jul 5, 2018
Actual Primary Completion Date :
Apr 24, 2020
Actual Study Completion Date :
Jan 5, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Pulsed Radiofrequency Group

This group will undergo pulsed radiofrequency treatment.

Procedure: Pulsed Radiofrequency treatment
The pulse treatment generator (PMF-21-100-5, Baylis Medical Inc., Montreal, Canada) with a length of 10 cm, 21-gauge, and an active tip length of 5 mm is inserted vertically into the puncture point. The pulse treatment generator is set to the pulsed radiofrequency automatic mode, with a temperature of 42 °C, pulse frequency of 2 Hz, pulse width of 20 ms, and treatment duration of 360s.

Active Comparator: Nerve Block Group

This group will undergo nerve block treatment.

Procedure: Nerve Block treatment
A mixture of 40 mg Triamcinolone + 2 ml of 1% Bupivacaine + 2 ml of 2% mepivacaine + 1:100000 epinephrine is injected for nerve block treatment using a puncture needle.

Outcome Measures

Primary Outcome Measures

  1. Duration of the cluster period [Within 1 year (the cluster period is not over 3 months generally)]

    The duration of the cluster period is defined as the total duration of the headache, including the pain attack time before and after treatment.

Secondary Outcome Measures

  1. The degree of pain during headache attacks after treatment [1 day, 3 days, 1 week, 2 weeks, 1 month, 3 months, 6 months, and 1 year after surgery]

    Evaluated by numeric rating scale (NRS, 0 points for no pain and 10 points for the most severe pain)

  2. Headache attack frequency [1 day, 3 days, 1 week, 2 weeks, 1 month, 3 months, 6 months, and 1 year after surgery]

    The number of attacks per day

  3. Duration of each headache attack [1 day, 3 days, 1 week, 2 weeks, 1 month, 3 months, 6 months, and 1 year after surgery]

    Duration of each headache attack after treatment

  4. Dose of auxiliary analgesic drugs [1 day, 3 days, 1 week, 2 weeks, 1 month, 3 months, 6 months, and 1 year after surgery]

    Dose of auxiliary analgesic drugs per day

  5. Duration of remission period [1 day, 3 days, 1 week, 2 weeks, 1 month, 3 months, 6 months, and 1 year after surgery]

    From the end of this cluster period to the beginning of the next cluster period

  6. Patient satisfaction [1 day, 3 days, 1 week, 2 weeks, 1 month, 3 months, 6 months, and 1 year after surgery]

    Patient satisfactory scale (PSS) evaluation (0 for unsatisfactory, and 10 for very satisfied).

  7. Effective rate [1 day, 3 days, 1 week, 2 weeks, 1 month, 3 months, 6 months, and 1 year after surgery]

    The effectiveness rate is calculated as follows: effectiveness rate = the number of effective patients / total number of patients in this group × 100%.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 60 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • diagnosis of cluster headache is confirmed according to the diagnostic criteria of the 2018 International Classification of Headache Disorders 3rd edition (ICHD-3);

  • patient's age is between 18 and 60 years;

  • patients seek treatment in the pain clinics of hospitals participating in the study within 5 days of the onset of the cluster period; pain conditions of patients remain the same after conservative treatment of conventional oral medication, or the reduction rates are less than 50% in pain degree during headache attacks, headache attack frequency, duration of each headache attack, and auxiliary analgesic drug dosage; and

  • patients signed the informed consent.

Exclusion Criteria:
  • abnormalities in blood measurements, liver and kidney function, blood glucose, coagulation, electrocardiogram, and chest radiograph;

  • infection at the puncture site;

  • previous mental illness;

  • previous history of narcotic drug abuse;

  • history of anticoagulant and antiplatelet aggregation drugs;

  • implantable pulse generator;

  • previous history of invasive treatments such as sphenopalatine ganglion radiofrequency thermocoagulation and chemical destruction;

  • pregnant or breastfeeding patients.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Beijing Tiantan Hospital Beijing Beijing China 100050
2 Beijing Sanbo Brain Hospital Beijing Beijing China 100093
3 Jilin Province People's Hospital Changchun Jilin China 130021

Sponsors and Collaborators

  • Beijing Tiantan Hospital
  • Beijing Sanbo Brain Hospital
  • Jilin Province People's Hospital

Investigators

  • Principal Investigator: Fang Luo, M.D., Beijing Tiantan Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Fang Luo, Director of Department of Pain Management, Beijing Tiantan Hospital
ClinicalTrials.gov Identifier:
NCT03567590
Other Study ID Numbers:
  • KY 2018-027-02
First Posted:
Jun 26, 2018
Last Update Posted:
Oct 26, 2021
Last Verified:
Oct 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Fang Luo, Director of Department of Pain Management, Beijing Tiantan Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 26, 2021